AstraZeneca's acquisition of Zegfrovy and J&J's earnings announcement signal a major shift in the oncology market.
AstraZeneca Secures Global Rights to Zegfrovy
AstraZeneca (AZN) has acquired global rights to Zegfrovy (sonvortinib), a non-small cell lung cancer (NSCLC) treatment, from Dizal. The deal, valued at $600 million upfront and up to $1.5 billion total, is a strategic move to enhance AstraZeneca's oncology portfolio. Zegfrovy, already approved in the US and China, generated $85 million in revenue in fiscal year 2025. With competitors like Cullinan emerging, AstraZeneca's proactive acquisition of a proven asset aims to solidify its leading position in the NSCLC market.
J&J's Oncology Segment Faces Challenges
Johnson & Johnson (JNJ) saw its stock price decline nearly 3% despite raising its 2026 revenue forecast. While Darzalex, a multiple myeloma treatment, showed growth, sales of Erleada (prostate cancer) and Imbruvica (blood cancer) fell short of expectations. Wall Street is concerned that the slowdown in J&J's oncology segment, a key growth driver, could lead to long-term growth challenges. This highlights the importance of a robust pipeline for even large pharmaceutical companies to withstand patent expirations and increased competition.
Spero Pivots to Immunology with IBI355 Acquisition
Spero Therapeutics (SPRO) has acquired rights to IBI355 (SP001), a CD40 ligand (CD40L) targeting antibody, from Innovent Biologics. Spero is shifting away from traditional antibiotic development and plans to initiate a Phase 2 clinical trial for IgG4-related disease (IgG4-RD) next year. Innovent will receive up to $1.1 billion in milestone payments and will continue its own development of IBI355 for Sjögren's syndrome. This reflects a trend among smaller biotech companies to rapidly reposition themselves towards the autoimmune disease market, which has significant unmet medical needs.
Biotech Companies Secure Major Funding Rounds
Chai Discovery and AdvanCell have both successfully secured significant funding rounds despite the challenging economic climate. Chai Discovery, an AI-powered molecular design company, raised $400 million in a Series C round, valuing the company at $3.8 billion, and is expanding its collaborations with companies like Pfizer. AdvanCell, a radiopharmaceutical startup, raised $315 million in a Series D round to accelerate clinical trials for a prostate cancer treatment. This demonstrates a growing trend of global capital flowing into companies with innovative modalities.
AstraZeneca's (AZN) acquisition of Zegfrovy for $600 million upfront and up to $1.5 billion total, with its existing $85 million in annual revenue, positions the drug as a key driver in the NSCLC market, competing with Cullinan and contributing to AstraZeneca's goal of reaching $80 billion in annual revenue. Meanwhile, J&J's underperformance of existing products like Erleada and Imbruvica signals the risk of portfolio aging for large pharmaceutical companies and will likely accelerate the competition for innovative oncology pipelines. Chai Discovery's $400 million Series C funding and AdvanCell's $315 million Series D funding highlight the increasing concentration of capital in AI-driven molecular design and targeted alpha therapy (TAT). Finally, Spero's (SPRO) acquisition of IBI355 from Innovent for up to $1.1 billion and its pivot to autoimmune disease development represents a broader trend of portfolio repositioning among smaller biotech companies.
Source: BioPharma Dive (rss)